Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy) induced durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL), including patients who relapsed after CAR T-cell therapy. The findings were presented at the recent American Society of Hematology (ASH) annual meeting and simultaneously published in Nature Medicine. In this […]
Adcetris Plus Chemo Effective in HIV-Related Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) was effective for patients with HIV-related stages II-IV classical Hodgkin lymphoma (cHL), according to results from the phase I/II AMC-085 study. All 37 patients who completed therapy in the 41-patient trial achieved a complete response; at 2 years, the progression-free survival (PFS) rate reached […]
FDA Greenlights New First-Line Regimen in Bladder Cancer
The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday. Specifically, the combination is indicated for those who are ineligible for cisplatin-containing chemotherapy, and the approval marks the first anti-PD-1/antibody-drug conjugate combination for this patient […]
Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma
CHICAGO — A combination of brentuximab vedotin (Adcetris) and chemotherapy was safe and effective in pediatric patients (up to age 21 years) with newly diagnosed high-risk Hodgkin lymphoma, a researcher reported here. In the phase III study, a regimen of brentuximab vedotin (Bv) combined with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide chemotherapy (AVE-PC) was superior […]